Affimed N.V.
Affimed is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE ® ) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE ® are generated on the Company’s proprietary ROCK ® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells. A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by the bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.
Price sits at 13% of its 52-week range.
Current Price
$0.18
+0.00%Affimed N.V. (AFMD) Insider Trades
AFMD Insider Trading Activity
Track insider trading transactions for Affimed N.V. (AFMD). Monitor recent buys, sells, and option exercises by officers, directors, and 10% beneficial owners. Insider trading activity can signal management confidence or concern about a stock's future prospects.
Current stock price: $0.18. Market cap: $2.78M. This page displays the most recent insider transactions for AFMD, including the insider's name, title, transaction type (purchase, sale, or option exercise), number of shares, and total value. Filter transactions by type to focus on open-market purchases or sales.
Insider buying is often viewed as a bullish signal, as insiders are putting their own capital at risk. Conversely, large insider sales may warrant further investigation. Use GoodMoat's insider trading data alongside financial analysis, quality scores, and valuation tools for a comprehensive view of Affimed N.V.'s investment outlook.